Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

PCRX

+ Watchlist+ Portfolio

Pacira BioSciences, Inc.

Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$36.48
52-Week Range
$18.80 – $36.67
Market Cap
$1.46B
P/E (TTM)
39.23
EPS (TTM)
0.93
Dividend Yield
0.00%
Advanced Metrics
Price/Book
2.04
PEG Ratio
0.99
Return on Equity
5.24%
Return on Assets
1.49%
Gross Margin
77.85%
Operating Margin
4.00%
Profit Margin
5.08%
Current Ratio
4.68
Debt/Equity
0.48
Total Debt
$340.28M
Free Cash Flow
$187.77M
Revenue Growth
-1.60%
Earnings Growth
483.30%
Enterprise Value
$1.51B

Market Snapshot

About

Pacira BioSciences is a commercial-stage pharmaceutical company focused on non-opioid pain management and regenerative health solutions. The company markets EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic used in surgical settings to manage post-operative pain. Pacira also offers ZILRETTA for osteoarthritis knee pain and iovera° for peripheral nerve treatment. The company is committed to advancing non-opioid alternatives to help reduce opioid use and is headquartered in Parsippany, New Jersey.